Deals of the Week: Allergan/MAP, Actavis/Uteron, Baxter/Ipsen, and More
Executive Summary
Allergan’s buyout of MAP Pharma is an unusual case of a deal centered on drug under the shadow of a “complete response” letter, but it’s not the only one. How does it compare to recent precedents.
You may also be interested in...
Ipsen Relocates U.S. R&D To Cambridge, Mass., Biotech Hub
The French pharma is the latest company to move its researchers closer to the center of vibrant academic and medical research in Cambridge, Mass.
Dezima Pharma Raises $18.6 Million For Next-Generation CETP Inhibitor
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.
Deals Of The Week: Alnylam/The Medicines Co., Inspiration/Cangene, Pfizer/OxOnc
Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.